Finally, because the numbers of enrolled patients in the NEDA and EDA groups consisting of IFN-β-treated MS patients were relatively small in this study, our findings should be confirmed in a future study using a larger sample size. This evidence concerns the gene IFNB1 and myeloid sarcoma.